Edition:
United Kingdom

Spark Therapeutics Inc (ONCE.OQ)

ONCE.OQ on NASDAQ Stock Exchange Global Select Market

100.78USD
23 Aug 2019
Change (% chg)

-- (--)
Prev Close
$100.78
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
134,924
52-wk High
$114.20
52-wk Low
$34.59

About

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a... (more)

Overall

Beta: 2.02
Market Cap(Mil.): $3,837.80
Shares Outstanding(Mil.): 38.90
Dividend: --
Yield (%): --

Financials

  ONCE.OQ Industry Sector
P/E (TTM): -- 98.31 33.85
EPS (TTM): -2.36 -- --
ROI: -13.33 7.52 12.69
ROE: -18.65 7.94 17.13

Roche, Spark push back takeover deadline in $4.3 billion deal

ZURICH Roche and Spark Therapeutics agreed to extend the deadline for the Swiss drugmaker's $4.3 billion takeover bid for the U.S. gene therapy specialist, Roche said, adding it remains "fully committed" to a deal it sees closing this year.

08 Jul 2019

Roche, Spark push back takeover deadline in $4.3 billion deal

ZURICH Roche and Spark Therapeutics agreed to extend the deadline for the Swiss drugmaker's $4.3 billion (3.43 billion pounds) takeover bid for the U.S. gene therapy specialist, Roche said, adding it remains "fully committed" to a deal it sees closing this year.

08 Jul 2019

BRIEF-Roche And Spark Therapeutics Receive Information Request From Federal Trade Commission

* ROCHE AND SPARK THERAPEUTICS, INC. RECEIVE REQUEST FOR ADDITIONAL INFORMATION FROM FTC UNDER HART-SCOTT-RODINO ACT AND ANNOUNCE EXTENSION OF TENDER OFFER FOR SHARES OF SPARK THERAPEUTICS, INC.

10 Jun 2019

Deals of the day-Mergers and acquisitions

May 14 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

14 May 2019

Catalent seeks slice of gene therapy market with Paragon buy

Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion (916.4 million pounds) in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.

15 Apr 2019

Catalent seeks slice of gene therapy market with Paragon buy

Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.

15 Apr 2019

UPDATE 3-Catalent seeks slice of gene therapy market with Paragon buy

April 15 Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.

15 Apr 2019

Catalent to buy Paragon Bioservices for $1.2 billion: WSJ

Drug developer Catalent Inc has agreed to buy privately held, gene-therapy focused Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

15 Apr 2019

UPDATE 1-Catalent to buy Paragon Bioservices for $1.2 bln -WSJ

April 14 Drug developer Catalent Inc has agreed to buy privately held, gene-therapy focused Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

15 Apr 2019

Biogen to buy Nightstar Therapeutics in $800 mln cash deal

Biogen Inc said on Monday it will buy Nightstar Therapeutics Plc for about $800 million in cash as the company looks to tap into a potentially lucrative gene therapy market.

04 Mar 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates